TIBSOVO (ivosidenib tablets), for oral use. Initial U.S. Approval: 2018

FDA approved Anti-Cancer medicine TIBSOVO (ivosidenib tablets) is available upon request. Get best retail price of TIBSOVO (ivosidenib tablets) from trusted online pharmacy. For emergency product orders call 8750295029 (Mr. Neeraj Nagpal) or For enquires email urgent@medvitaz.com. For advanced treatments in India, Medvitaz Pharma Solution can even help patient to discuss with Medical Oncologist.
Categories: , .

TIBSOVO (ivosidenib tablets), for oral use. Initial U.S. Approval: 2018

INDICATIONS AND USAGE
TIBSOVO is an isocitrate dehydrogenase-1 (IDH1) inhibitor indicated for the treatment of adult patients with relapsed or refractory acute myeloid leukemia (AML) with a susceptible IDH1 mutation as detected by an FDA-approved test.
DOSAGE FORMS & STRENGTHS
Tablets: 250 mg
Manufactured By: Agios Pharmaceuticals
Prescribing Information URL: Click Here

HOW TO MAKE AN ENQUIRY FOR TIBSOVO (ivosidenib tablets)?

FDA approved Anti-Cancer medicine TIBSOVO (ivosidenib tablets) is available upon request. Get best retail price of TIBSOVO (ivosidenib tablets) from trusted online pharmacy. For emergency product orders call 8750295029 (Mr. Neeraj Nagpal) or For enquires email urgent@medvitaz.com. For advanced treatments in India, Medvitaz Pharma Solution can even help patient to discuss with Medical Oncologist.

Ivosidenib, sold under the brand name Tibsovo, is a medication for the treatment of acute myeloid leukemia (AML). It is a small molecule inhibitor of isocitrate dehydrogenase-1 (IDH1), which is mutated in several forms of cancer. The drug is being developed by Agios Pharmaceuticals and is in phase III clinical trials.[when?] The U.S. Food and Drug Administration (FDA) awarded orphan drug designation for acute myeloid leukemia and cholangiocarcinoma.
The U.S. Food and Drug Administration (FDA) considers it to be a first-in-class medication.
In 2018, ivosidenib was approved in the United States for relapsed or refractory acute myeloid leukemia (AML) with an IDH1 mutation and is presently[when?] in a phase III clinical trial for cholangiocarcinoma with an IDH1 mutation.
In 2019, ivosidenib was approved in the United States for newly diagnosed acute myeloid leukemia (AML) with a susceptible IDH1 mutation, as detected by an FDA-approved test, in patients who are at least 75 years old or who have comorbidities that preclude the use of intensive induction chemotherapy.

HOW AND WHERE TO BUY ivosidenib tablets?

You can order ivosidenib tablets direct from Medvitaz Pharma Solutions if the drug has not been approved or is not available in your country. We help you to get genuine, affordable and assurance of delivery. To get best retail price/cost of ivosidenib tablets in India, Call 8750295029 or Email urgent@medvitaz.comFDA approved drugs of Australia, Canada, Delhi, EU, India, New Zealand, Singapore, Switzerland, Turkey & USA.

neeraj
Neeraj Nagpal

Head of Operations

 The profound knowledge of more than 20 years in sales and marketing sector, he has been working dedicatedly and contributing to pharmaceuticals industry. He handles all operations over the country.

Contact Our Team

Contact us and we will reply as soon as possible!

    need help?

     MEDVITAZ is an initiative for helping end-users directly to get the right medicines and right medical treatments from the right source.